York acquires two products from Celltran

York Pharma has acquired certain assets and the continuing business of fellow UK-based Celltran from its administrators for L70,000 ($111,000), plus royalties on future sales for a period of five years. The firm says an institutional placing has raised L510,000 at 14.4 pence per share to provide additional working capital for the integration.

The acquisition further expands York Pharma's product offering in dermatology, providing two specialized, marketed products for the treatment of chronic wounds and burns, Myskin and Cryoskin. The two products are directly complementary to Flammazine and Flammacerium, both recently acquired by York, and will be marketed for the acute treatment and subsequent regeneration of the skin associated with burns and wounds.

The acquired pipeline includes: Lyphoderm, a cell-based medicinal product for the treatment of chronic wounds, which has successfully completed a Phase II trial conducted in 194 venous leg ulcer patients; Ulcodress, a state-of-the-art hydrogel wound dressing providing protease modulation; Myskin Vitiligo, a preclinical development product to treat vitiligo, an intractable condition of skin depigmentation; Myskin Cornea, a product in pre-clinical development to treat corneal damage using autologous cornea cells delivered to the patient on a specially developed contact lens.